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Background

Pharmacists have an opportunity to reduce opioid
overdoses and mortality, especially through the provision of
naloxone and education to patients and consumers at risk
of an overdose. Naloxone is a competitive opioid receptor
antagonist that reverses the respiratory neuroinhibitory
effects, resulting in temporarily stopping opioid overdoseinduced respiratory depression that may progress to apnea.8
There are studies reporting favorable results of naloxone
used among laypersons, police and emergency medical
first responders in reducing deaths associated with opioid
overdoses.9–11 Furthermore, there is growing public concern
and awareness of the negative and fatal consequences
associated with opioid misuse and overdose, but there is not
much reported about the community pharmacists’ response
and attitudes toward dispensing naloxone in California.
As a result, we performed a larger study as a follow-up to
our pilot study12 that evaluated the prevalence of naloxone
dispensing without a prescription in Orange County after
Assembly Bill (AB) 1535 was enacted in September 2016.
Of note, AB 1535 authorizes licensed California pharmacists
who have undergone a training program of at least one hour
of continuing education (CE) about naloxone hydrochloride to
be able to dispense naloxone without a prescription.35

Objective
This study aimed to assess pharmacists’ response to the
current opioid crisis in California, particularly regarding the
prevalence of naloxone furnishing (or dispensing without
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Methods
Study Design

This was a descriptive study of California licensed community
pharmacists working in chain and independent pharmacies.
A questionnaire was developed to evaluate pharmacists’
response to patients and consumers requesting naloxone.
Face validity of the questionnaire was assessed by a team
of four cross-disciplinary pharmacist experts with retail
experience at chain and independent pharmacies. Content
validity and comprehension of the questionnaire were tested
in our previous pilot study conducted in Orange County with
38 pharmacists.12 The questionnaire contained 28 multiplechoice and Likert-type questions that took approximately
five minutes to complete. The questionnaire items included
questions about the pharmacists’ demographics and length
of practice, whether they have received requests for naloxone
and treatments for OUD and pain in the past three months,
pharmacists’ attitudes about providing naloxone education
and using the Controlled Substance Utilization Review and
Evaluation System (CURES) as a prescription drug monitoring
program and existence of a pharmacy policy for naloxone
dispensing information. Additionally, we investigated the
number of naloxone units dispensed across California
counties. Completion of the questionnaire was voluntary
and anonymous. Our study was approved by our university’s
Institutional Review Board (IRB #18-95). The questionnaire
was conducted between March and September in 2018.

Participants

Eligible participants included being a California licensed
pharmacist working in a community pharmacy setting and
a member of the California Pharmacists Association (CPhA).
With the assistance of CPhA, the community pharmacist
members were sent an email with the questionnaire link.
There were two email attempts made to CPhA pharmacist
members to complete the questionnaire within the study
time frame. A second email was deployed three months after
deployment of the first one.

Statistical Analyses

Our sample of 77 pharmacists for degrees of freedom
up to 12 can detect a large effect size (w = 0.5) with 0.05
significance at a power of 0.85.13 We used Fisher’s exact test
if the number of samples in each category was less than five;
otherwise, an χ2 test was used. The most conservative multiple
testing adjustment, Bonferroni correction, was applied
to minimize false positive or type I error when evaluating
variables associated with naloxone dispensing.14 Spearman’s
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The opioid crisis continues to worsen in the U.S., with
increased fatal opioid overdoses increasing during the
COVID-19 pandemic. The Centers for Disease Control and
Prevention National Center for Health Statistics reported an
estimated 100,306 drug overdose deaths over one year (April
2020 to April 2021). This was an increase of 28.5% from
78,056 deaths the year before.1 Over the past decade, deaths
from opioid-related overdoses have almost tripled in the U.S.,
increasing from approximately 17,500 in 2006 to 42,200 in
2016.2 Along with the public health advisory on naloxone
and opioid overdose released by the surgeon general, the
Department of Human and Health Services declared the
opioid crisis a national public health emergency.3,4 There
were 70,237 overdose deaths reported in 2017, with more
deaths associated with fentanyl.5,6 Moreover, the top three
California counties by number of opioid overdose deaths in
2017 included Los Angeles, San Diego and Orange.7 Opioids
can be lethal, especially when taken at high doses and
combined with alcohol and/or other central nervous system
(CNS) depressant medications (i.e., benzodiazepines or
hypnotics).34

a prescription) and prescriptions for medication-assisted
treatment (MAT) drugs for opioid use disorder (OUD) to
patients and consumers.

correlation test was used for checking association. All
statistical analyses assumed a significance level of α = 0.05.

Results
Of the 1,612 California pharmacist recipients of the emailed
questionnaire, 118 (7.32%) partially responded and 79 (4.90%)
completed the questionnaire. Two of the 79 pharmacists were
excluded because they were not practicing in a community
pharmacy at the time of the study, resulting in 77 (4.78%)
pharmacists included in the study.

Among the 77 pharmacists who completed the questionnaire,
33 were female (42.9%) and 44 were male (57.1%). Forty-six
pharmacists (59.7%) worked in independent pharmacies,
14 (18.2%) in chain pharmacies and 17 (22.1%) in other
pharmacy settings, which included ambulatory care. The
counties with the higher number of pharmacists completing
the questionnaire included Los Angeles (n = 12), Orange (n =
6), Sacramento (n = 5), and San Diego (n = 5) (Table 1).

Naloxone Dispensed and Policy To Dispense
Without a Prescription

Most pharmacists (97.4%) were already aware of the California
AB 1535 legislation, which allows pharmacists to furnish
or dispense naloxone without a prescription.15 Fifty-three
pharmacists (68.8%) stocked naloxone in their pharmacies.

Despite being among the top three counties in California by
number of opioid-related deaths, the six pharmacists from
Orange County had not dispensed naloxone in the past three
months. Only two pharmacists from San Diego and Sonoma
counties reported dispensing more than five units of naloxone
in the past three months. Four out of 12 pharmacists from Los
Angeles County and 3 out of 5 pharmacists from San Diego
had dispensed at least one naloxone unit in the past three
months (Figure 1). These findings highlighted the discrepancy
between opioid overdose deaths and naloxone dispensing
when compared to the 2017 California opioid use data that
showed a significant correlation between the number of
opioid prescriptions dispensed and opioid overdose death.7

Figure 1. Bar graph of the self-reported number naloxone units dispensed across California counties as indicated by
participating pharmacists (n=77). Pink bars indicate pharmacies reportedly dispensing 1-5 naloxone units while light blue bar
indicate dispensing more than 5 naloxone units dispense within the last three months prior to survey completion.
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Demographics of Pharmacist Participants,
Pharmacy Settings, and Counties

However, only 11 pharmacists (14.3%) had furnished
naloxone in the past three months. Twenty pharmacists
(26.0%) responded that their patients requested the price
of naloxone (intranasal or intramuscular formulation) and 17
pharmacists (22.1%) reported that some patients declined to
purchase naloxone because it “was too expensive”. Similarly,
33 pharmacists (42.9%) reported having a policy in place for
naloxone education when naloxone is dispensed; 19 (24.7%)
reported having a policy to dispense naloxone to patients
who were prescribed a daily dose of ≥ 90 morphine milligram
equivalents (MME) and for more than 90 days; and 12 (15.6%)
had a policy to dispense naloxone to patients who were
prescribed both opioid and benzodiazepine prescriptions.

Amount of Naloxone Dispensed Versus
Buprenorphine/Naloxone and
Buprenorphine

Variables Associated With Naloxone
Dispensing Without Prescription

Within the completed responses, we investigated the
association of 12 variables with naloxone furnishing using
Fisher’s exact test or χ2 test (Table 3). After Bonferroni
correction of the P values for multiple testing, only three
variables were found to be statistically significant: units of
naloxone sold in the previous 3 months (P<.001, Fisher’s
Exact Test [FET]); whether pharmacists were asked for the
naloxone price (P<.001, FET); and whether patients declined
to purchase naloxone because of its cost (P<.001, FET) (Table
3). The results for two questions — whether pharmacists
were asked for the price of naloxone and whether patients
declined to purchase naloxone — were highly correlated
(Spearman correlation 0.994, P<.001).

Pharmacists’ comfort in Providing Naloxone
Education

Sixty-nine pharmacists (89.6%) felt very comfortable or
comfortable educating patients about naloxone use. However,
only two pharmacists (2.60%) felt uncomfortable in educating
patients about naloxone. Forty-seven pharmacists (61.0 %)
received a minimum one-hour CE about naloxone. Pearson’s
χ2 test did not show a significant relationship between how
comfortable pharmacists were about educating patients
regarding naloxone use and receiving a minimum one-hour
CE course. Pharmacists who received more than one hour
of CE reported feeling more comfortable regarding naloxone
patient education, but the difference was not significant (P
= .060). However, a significant relationship existed between
how comfortable pharmacists felt about naloxone education
and the number of practicing years (P = .003). In terms of the
format of naloxone training and education, most pharmacists
preferred an online course (67.6%), followed by attending live
workshops (48.1%).

Patient Counseling About Opioid
Dependence and Overdose Potential

When dispensing new opioid prescriptions, most pharmacists
reported counseling patients always (45.5%) or sometimes
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Pharmacists’ Attitudes About Using CURES
and Prescribers’ Usage of CURES

Seventy-two pharmacists (93.5%) believed checking CURES
is effective in preventing opioid abuse. However, 22 (28.6%)
strongly disagreed or disagreed that they have enough time
to check CURES every time they filled an opioid prescription.
Most pharmacists strongly agreed or agreed that prescribers
should check CURES every time an opioid is prescribed
for new patients (96.1%), acute pain (93.5%), chronic
pain (92.2%), and concurrent opioid with benzodiazepine
prescriptions (92.2%) (Table 4).

Discussion
In response to the opioid crisis, many states have expanded
the pharmacists’ legal functions to dispense naloxone
without a prescription, with a standing order or under
protocol as naloxone providers and first responders.15-20 Our
study findings showed that there were significantly more
prescriptions dispensed for MAT drugs (buprenorphine/
naloxone and buprenorphine) than for naloxone. One
possible reason for this could be that prescribers may
be selecting alternatives to opioids to treat their patients’
pain and attempt to reduce the risks associated with
opioid dependence, addiction or a precipitated opioid
withdrawal.21,22,36 In spite of naloxone being safe and effective
as a rescue medication for opioid overdoses, precipitated
or an acute opioid withdrawal syndrome could occur in
individuals who are opioid dependent. These individuals
could experience agitation, sweating, pain, vomiting and flulike symptoms after receiving naloxone.36 On another note,
a previous survey found that only 23.5% of the California
community pharmacies were dispensing naloxone to patients
without a prescription.23 However, the study did not evaluate
whether the pharmacies were dispensing prescriptions of
MAT for OUD in place of naloxone as our study has done. In
any case, both studies found a very low rate of dispensing
naloxone without a prescription by community pharmacists.
Despite the rising opioid-related mortality in the U.S., the
annual number of naloxone prescriptions modestly increased
from 2.8 million to 3.2 million between 2009 and 2015.24
Furthermore, the CDC reports that prescriptions for naloxone
and buprenorphine have increased only marginally in the past
three years.1
Since 2016, the California State Board of Pharmacy has
provided naloxone training to over 700 pharmacists as part
of the implementation process of AB 1535.23 However, the
rate of naloxone dispensing with or without a prescription
appeared to be low among community pharmacists. Some
potential reasons for the low dispensing rate could include
the pharmacies’ decision not to stock naloxone, lack of time
to educate patients about naloxone and stigma associated
with patients or consumers requesting naloxone.25,26 Another
possible reason for the low dispensing rate could be that
some pharmacists have not completed the required one-
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Forty-six pharmacists dispensed at least one of these
medications: naloxone, buprenorphine/naloxone and
buprenorphine. However, only 43 pharmacists reported the
number of units dispensed. Because of the large variation in
the number of units dispensed (0 to 200), we categorized the
reported dispense of these units into three categories: less
than three, between three and 30, and greater than 30 in the
past three months. Most prescriptions contained naloxone
alone or in combination with buprenorphine (Table 2). The
total naloxone units dispensed (n = 396) were lower compared
to dispensed MAT drugs for OUD, such as buprenorphine/
naloxone (n = 1,116) and buprenorphine (n = 508). This
finding indicated the overall dispensing of naloxone was
low. Only 33 pharmacists (42.9%) dispensed naloxone, and
most with a prescription (31 or 40.3%). Interestingly, there
were 31 pharmacists (40.3%) who did not dispense any of
the three medications: naloxone, buprenorphine/naloxone, or
buprenorphine.

(29.9%) about the dependence potential and the risk of
accidental opioid overdose. However, five pharmacists
(6.49%) did not counsel patients when dispensing new opioid
prescriptions, and nine pharmacists (11.7%) did not counsel
patients when dispensing recurring opioid prescriptions.
Fourteen pharmacists (18.2%) had not dispensed opioid
prescriptions in the past three months.

hour CE naloxone education.15 More recently, California
AB 2760 was enacted in January 2019 and requires coprescribing naloxone for high-risk patient groups (i.e., those
receiving a daily prescription dosage of ≥ 90 MME of an
opioid medication or concurrent prescriptions for other CNS
depressants, having a history of opioid-related ED visit or
prior overdose and having a personal or family history of
substance use disorder).27 Further studies could evaluate if
the number of naloxone prescriptions will increase as a result
of this new legislation.

Regarding the pharmacists’ knowledge and comfort level
of training and educating patients about naloxone, those
who have been practicing for more than 10 years expressed
feeling comfortable in providing naloxone education and
training to patients. In contrast, pharmacists who practiced
for less than 10 years expressed feeling less comfortable
about providing patient education about naloxone. There
is clearly an educational need to provide further naloxone
training opportunities for pharmacists to ensure that they feel
adequately trained.
The majority of pharmacists felt that checking CURES was
important for both pharmacists and prescribers in their
effort to monitor opioid overprescribing, dispensing and
improving clinical decision-making when prescribing opioid
prescriptions for their patients. However, the pharmacists
expressed concerns about the extra time needed to check
CURES while trying to avoid long waiting times for patients
because of their busy work schedules. The findings of this
study suggest the need for expanding the pharmacists’
counseling to include patients on new and recurring opioid
prescriptions at daily doses ≥ 90 MME. Further studies could
assess why these patients refuse counseling or other reasons
for the low reported counseling rates.
With the continued opioid crisis occurring nationally,
we should expect more demand of naloxone within our
communities. A recent publication projected that 700,400
individuals will die from an opioid overdose between 2016
to 2025, with 80% of those deaths attributable to illicit
opioids, such as heroin and synthetic fentanyl.29 With more
restrictions and scrutiny on opioid prescriptions, the number
of individuals who will be using illicit opioids is projected to
increase by 61%, or from 0.93 million in 2015 to 1.5 million
individuals by 2025.29 Current interventions aimed at lowering
the incidence of prescription opioid misuse (i.e., prescription
drug monitoring programs, substance use education and
prevention, alternative pain management and harm reduction)
may have some effect, however, the opioid crisis is predicted
to worsen in the next decade.29 The reality is that more people
are starting with illicit opioids than with prescription opioids.30
Moreover, infiltration of the heroin supply with highly potent
synthetic opioid fentanyl and carfentanil is increasing the
lethality of illicit opioids.31,32 As a result, promoting broader
awareness and easier access to naloxone within our
communities as well as expanding the role of the pharmacist
are key to preventing opioid overdose deaths.

There were some limitations to this study. Owing to the
low response rate of the survey, the questionnaire results
assessed from the cohort of pharmacist participants may not
be generalizable to the community pharmacists in California.
We note that the descriptive statistical analyses are based
on complete responses rather than total survey distribution.
Also, the study sample was comprised mostly of community
pharmacists. However, there could be pharmacists in other
settings who may also dispense naloxone in other settings
(e.g., emergency department). Therefore, study selection
bias may not capture the true variability regarding naloxone
dispensing in the pharmacist population. Of note, pharmacists
may not have naloxone in their pharmacies or use the same
protocol for calculating MME to be able to identify highrisk patients and the opportunity to dispense naloxone.
Finally, the validity of the study results may be affected by
self-report, recall and perception-based bias. Thus, further
research is needed to assess and validate these results in a
larger pharmacist population.

Conclusion
The provision of naloxone in California community
pharmacies continues to remain low since the approval of
AB 1535 that authorizes pharmacists to dispense naloxone
without a prescription. As the opioid epidemic continues
to devastate our communities, there is an urgent need to
expand the availability and affordability of naloxone in our
communities. A multipronged and multilayered approach
and commitment from various key stakeholders need to
happen to reduce naloxone access barriers for patients
and consumers. For instance, more education and training
programs about naloxone should be offered in high schools,
universities, and health professional schools to broaden the
public’s awareness about naloxone’s life-saving potential.
Policymakers, drug manufacturers and third-party insurers
should make naloxone available as an over-the-counter
medication and more affordable to increase its access to
patients and consumers.33 More importantly, future harm
reduction programs should be developed to address the
availability and affordability of naloxone and implement
opioid overdose education and naloxone distribution
training programs to consumers and health care providers
in California.
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Similarly, the high price of naloxone could reduce the
affordability to many patients and consumers who pay outof-pocket for naloxone. The generic naloxone injectable or
intranasal vial (2 mg/2 mL), which could be used with the
mucosal atomizer device, is approximately $40.28
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